In August, the agency warned that many people are overdosing on alternatives to Ozempic and Wegovy due to the do-it-yourself ...

The costs for 806 patients with overweight or obesity and heart failure were analyzed in one study. For those patients, the average total medical costs dropped from $29,654 before treatment began to ...

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Osteoarthritis of the knee is a common and often painful condition affecting millions worldwide, especially older adults. As ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...